Agilis Biotherapeutics is a developer of DNA-based therapeutics designed to treat life-threatening or fatal rare diseases. The company's transformative approach delivers a corrected copy of a naturally occurring gene directly to targeted cells, providing long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Its technology enables precise targeting and restoration of lost gene function while avoiding unintended off-target effects. The company offers DNA therapeutics for AADC Deficiency, Friedreich’s Ataxia, and Angelman Syndrome, and has a strategic partnership with Intrexon Corporation.